Breakthrough Injection Frees Patients from Steroid Pills

Severe asthma patients may soon ditch daily steroid tablets thanks to a groundbreaking monthly injection. Tezepelumab, a new biologic therapy, effectively targets the root cause of airway inflammation, offering a promising alternative to oral steroids. This innovative treatment was recommended for patients over 12 whose usual medications were insufficient.

The Wayfinder trial, involving nearly 300 individuals across 11 countries, demonstrated remarkable results. A significant 90% of participants successfully reduced their steroid tablet intake, and over half were able to cease daily steroids altogether within a year. This offers relief from the often-debilitating side effects associated with prolonged steroid use.

Beyond reducing steroid dependency, Tezepelumab also showed a dramatic impact on asthma control. Two-thirds of patients remained free from asthma attacks for the entire year-long study period, with improvements noted as early as two weeks. Researchers are optimistic this therapy could transform care for those with the most challenging asthma cases.